SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Product
RxNorm 2468233

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2468233 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Product.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDG
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Product
AUI:12521623
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDGPrescribable

Semantic Clinical Dose Form Group (SCDG):
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Product
(Atom ID: 12521623)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Product
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2468233
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12521623
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDG
Semantic Clinical Dose Form Group (Ingredient + Dose Form Group)
Source Code
2468233
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AVAILABLE STRENGTH
0.0075 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2) / 0.0075 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.01 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (KP.2))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.025 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273) / 0.025 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.025 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2) / 0.025 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.0333 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (KP.2))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.0333 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (LP.8.1))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.05 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273) / 0.05 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.05 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1283 OMICRON (LP.8.1))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.05 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2) / 0.05 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.1 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (KP.2))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.1 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (LP.8.1))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.1 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (KP.2))
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
0.1 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (LP.8.1))
Available drug strengths listed in the order of ingredients from the drug